News

BIO-CAT Gains Organic Certification to Meet the Growing Demands of Consumers

As consumer demand for clean-label, organic, and non-GMO products continues to surge, the pressure is mounting on ingredient suppliers to meet stringent certification standards and scale production accordingly.

As the “food as medicine” movement gains traction and shoppers report increasing their purchases of natural (23%) and organic (22%) products over the last six months, the message is clear: the future of food is clean, and suppliers must rise to the occasion—or risk being left behind*.

According to industry research, sales of natural, organic, and functional products grew by 6.6%, while conventional product sales declined by 0.2%**. This growth is largely driven by consumers prioritizing health, transparency, and sustainability. Organic and non-GMO certifications remain the top two attributes driving purchasing decisions—with 65% of shoppers stating they are more likely to buy a product that carries either the USDA Organic or Non-GMO Project Verified seal***.

This consumer demand is now aligning with policy, as the White House Administration echoes the need for increased access to organic options. “All Americans deserve access to clean, organic, healthy food for our families and children,” states the MAHA Action website. “Major food companies need to take accountability and responsibility for the ingredients that they put in our food and how they market their products to consumers.”

However, meeting this rapidly growing demand is no easy feat. Becoming organic certified requires a rigorous inspection process and adherence to strict federal standards prohibiting the use of synthetic pesticides, GMOs, and growth hormones. As brands shift toward clean formulations, ingredient suppliers are being called upon to deliver at scale—without compromising on integrity or quality.

Two companies rising to meet this challenge are BIO-CAT, Inc. (Troy, VA) and BIO-CAT Microbials, LLC (Shakopee, MN), both of which have successfully achieved Organic Certification through QAI (Quality Assurance International), a leading certification body under the USDA National Organic Program. This certification also extends to their branded products, OPTIZIOME P3 HYDROLYZER® from BIO-CAT, Inc. and OPTIBIOME BS50® from BIO-CAT Microbials, Inc.

“BIO-CAT is committed to producing top-quality products for our customers,” said Robert Boyd, Director of Compliance for both companies. “Achieving organic certification for our facilities is another level of quality that we have implemented into our operations, as well as for the ingredients we produce.”

As the leader in enzyme solutions and probiotic strain development and fermentation, BIO-CAT and BIO-CAT Microbials understand that this certification is critical for both their customers and to continue to demonstrate their leadership role in the industry. “BIO-CAT and BIO-CAT Microbials are proud to support the growing natural product movement with a robust portfolio of non-GMO enzymes and non-GMO microbials” stated Chris Schuler, CEO & Founder of BIO-CAT and BIO-CAT Microbials. “I look forward to our team sharing this information with the industry at Vitafoods Europe in Barcelona this week.”

Learn more here.

Recent News

02/03/2026

SSI Diagnostica Group Acquires InDevR

SSI Diagnostica Group, a global company specializing in testing solutions for infectious diseases, has announced the acquisition of InDevR, a Colorado-based provider of advanced multiplexed solutions for vaccine testing and quality control. The addition strengthens SSID Group’s leadership in pneumococcal vaccine QC testing with next-generation multiplexing assays and enhanced customization capabilities. InDevR will advance the Group’s offering by

02/02/2026

Accorto Regulatory Solutions Launches Dedicated Quality & Compliance Division

Accorto Regulatory Solutions, LLC (Accorto), a U.S.-based regulatory advisory firm, announced the launch of its dedicated Quality & Compliance Division, expanding the firm’s ability to deliver integrated regulatory and compliance support to organizations involved in the development of FDA-regulated products. The new division formalizes and expands Accorto’s compliance and GxP services in response to growing

01/29/2026

NIRSense, Inc. & Aspen Medical USA (AMUSA): Strengthening Frontline Medicine: U.S.–Developed Tissue Oxygenation Technology Delivered to Ukraine

NIRSense and Aspen Medical USA (AMUSA) are pleased to announce the donation of 12 portable tissue-ischemia monitoring kits (comprising advanced sensor consoles plus tablets) to the Ministry of Defence of Ukraine (MoD) for deployment in frontline Role-1 and Role-2 casualty care facilities in Ukraine. These investigational prototype systems are provided for use by military medical